Neoadjuvant therapy in locally advanced breast cancer: 99mTc-MIBI mammoscintigraphy is not a reliable technique to predict therapy response

Breast

Volumn 16, Issue 3, 2007, Pages 262-270

  Travaini, Laura Lavinia ^a   Baio, Silvia Melania ^a   Cremonesi, Marta ^a   Cicco, Concetta De ^a   Ferrari, Mahila ^a   Trifirò, Giuseppe ^a   Prisco, Gennaro ^a   Viale, Giuseppe ^a   Colleoni, Marco Angelo ^a   Radice, Davide ^a   Sivolapenko, Gregory B ^b   Paganelli, Giovanni ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

Adjuvant therapy; Breast tumor; Mammoscintigraphy; Multidrug resistance; Therapy response

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINATE CALCIUM; GONADORELIN ANTAGONIST; LETROZOLE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NAVELBINE;

ADVANCED CANCER; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER ADJUVANT THERAPY; CANCER PATIENT; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RELIABILITY; SCINTIMAMMOGRAPHY; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 34249099083     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2006.12.009     Document Type: Article

References (40)

1. Piwnica-Worms D., Kronauge J.F., and Chiu M.L. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation 82 (1990) 1826-1828
2. Delmon-Moingeon L.I., Piwnica-Worms D., Van den Abbeele A.D., Holman B.L., Davison A., and Jones A.G. Uptake of the cation hexakis (2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro. Cancer Res 50 (1990) 2198-2202
3. Carvalho P.A., Chiu M.L., Kronauge J.F., et al. Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts. J Nucl Med 33 (1992) 1516-1522
4. Piwnica-Worms D., Chiu M.L., Budding M., Kronauge J.F., Kramer R.A., and Croop J.M. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 53 (1993) 977-984
5. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2 (2002) 48-58
6. Ciarmiello A., Del Vecchio S., Silvestro P., et al. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 16 (1998) 1677-1683
7. Faneyte I.F., Kristel P.M., and van de Vijver M.J. Determining MDR17P-glycoprotein expression in breast cancer. Int J Cancer 93 (2001) 114-122
8. Takamura Y., Miyoschi Y., Taguci T., and Noguci S. Prediction of chemotherapeutic response by Technetium 99m-MIBI scintigraphy in breast carcinoma patients. Cancer 15 (2001) 232-239
9. Fisher B., Brown A., Mamounas E., et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15 (1997) 2483-2493
10. Fischer B., Bryant J., Wolmark N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16 (1998) 2672-2685
11. Von Minckwitz G., Costa S.D., Eiermann W., et al. Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 17 (1999) 1999-2005
12. Buzdar A.U., Singletary S.E., Theriault R.L., et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 17 (1999) 3412-3417
13. Hendrikse N.H., Franssen E.J., van der Graaf W.T., Vaalburg W., and de Vries E.G. Visualization of multidrug resistance in vivo. Eur J Nucl Med 26 (1999) 283-293
14. Vergote J., Moretti J.L., de Vries E.G., and Garnier-Suillerot A. Comparison of the kinetics of active efflux of 99mTc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes. Eur J Biochem 252 (1998) 140-146
15. Del Vecchio S., Ciarmiello A., Pace L., et al. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. J Nucl Med 38 (1997) 1348-1351
16. Litman T., Druley T.E., Stein W.D., and Bates S.E. From MDR to MXR: new understanding of multidrug resistance system, their properties and clinical significance. Cell Mol Life Sci 58 (2001) 931-959
17. Weidner N., Semple J.P., Welch W.R., and Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324 (1991) 1-8
18. Mankoff D.A., Dunwald L.K., Gralow J.R., Ellis G.K., Drucker M.J., and Livingston R.B. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi mammoscintigraphy. Cancer 85 (1999) 2410-2423
19. Hayward J.L., Carbone P.P., Heuson J.-C., Kumaoka S., Segaloff A., and Reubens R.D. Assessment of response to therapy in advanced breast cancer. Cancer 39 (1977) 1289-1294
20. Colleoni M., Minchella I., Mazzarol G., et al. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesteron receptors. Ann Oncol 11 (2000) 1-3
21. Hortobagyi G.N. Comprehensive management of locally advanced breast cancer. Cancer 66 (1990) 1387-1391
22. Colleoni M., Nole F., Minchella I., et al. Preoperative chemotherapy and radiotherapy in breast cancer. Eur J Cancer 34 (1998) 641-645
23. Schwartz G.F., Birchansky C.A., Komarnicky L.T., et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 73 (1994) 362-369
24. Sharma R., Mondal A., Shankar L.R., et al. Differentiation of malignant and benign solitary thyroid nodules using 30- and 120-minute tc-99m MIBI scans. Clin Nucl Med 29 (2004) 534-537
25. Fonti R., Del Vecchio S., Zannetti A., et al. Functional imaging of multidrug resistant phenotype by 99mTc-MIBI scan in patients with multiple myeloma. Cancer Biother Radiopharm 19 (2004) 165-170
26. Minai O.A., Raja S., Mehta A.C., et al. Role of Tc-99m MIBI in the evaluation of single pulmonary nodules: a preliminary report. Thorax 55 (2000) 60-62
27. De Cicco C., Trifiro G., Baio S.M., et al. Clinical utility of 99mTc-sestamibi mammoscintigraphy in the management of equivocal breast lesions. Cancer Biother Radiopharm 19 (2004) 621-626
28. Kao C.H., ChangLai S.P., Chieng P.U., and Yen T.C. Technetium-99m-methoxyisobutylisonitrile chest imaging of small cell lung carcinoma. Cancer 83 (1998) 64-68
29. Tabuenca M.J., Vargas J.A., Varela A., Salas C., Durantez A., and Ortiz Berrocal J. Correlation between 99m Tc-tetrofosmin uptake and P-glycoprotein expression in non-small-cell lung cancer. Rev Esp Med Nucl 17 (1998) 427-434
30. Burak Z., Ersoy O., Moretti J.L., et al. The role of 99mTc-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: comparison with therapy response. Eur J Nucl Med 28 (2001) 1341-1350
31. Kostakoglu L., Uysal U., Ozyar E., et al. Monitoring response to therapy with thallium-201 and technetium-99m-sestamibi SPECT in nasopharyngeal carcinoma. J Nucl Med 38 (1997) 1009-1014
32. Del Vecchio S.D., Ciarmiello A., Potena M.I., et al. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Eur J Nucl Med 24 (1997) 150-159
33. Fuster D., Munoz M., Pavia J., et al. Quantified 99mTc-MIBI scintigraphy for predicting chemotherapy response in breast cancer patients: factors that influence the level of 99m Tc-MIBI uptake. Nucl Med Commun 23 (2002) 31-38
34. Sciuto R., Pasqualoni R., Bergomi S., et al. Prognostic value of (99m)Tc-sestamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy. J Nucl Med 43 (2002) 745-751
35. Dunnwald L.K., Gralow J.R., Ellis G.K., et al. Residual tumor uptake of 99mTc-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival. Cancer 103 (2005) 680-688
36. Marshall C., Eremin J., El-Sheemy M., Eremin O., and Griffiths P.A. Monitoring the response of large (>3 cm) and locally advanced (T3-4, N0-2) breast cancer to neoadjuvant chemotherapy using (99m)Tc-Sestamibi uptake. Nucl Med Commun 26 (2005) 9-15
37. Bellon J.R., Livingston R.B., Eubank W.B., et al. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol 27 (2004) 407-410
38. Schelling M., Avril N., Nährig J., et al. Positron emission tomography using [18Ffluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18 (2000) 1689-1695
39. Dose Schwarz J., Bader M., Jenicke L., Hemminger G., Janicke F., and Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 46 (2005) 1144-1150
40. Eubank W.B., and Mankoff D.A. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 35 (2005) 84-99